Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib
Treatment with the tyrosine kinase inhibitor imatinib is the standard of care for newly diagnosed patients with chronic myeloid leukemia. In recent years, several second-generation inhibitors – such as dasatinib and nilotinib – have become available: these promise to overcome some of the mutations a...
Gorde:
| Egile Nagusiak: | , , , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Ferrata Storti Foundation
2014-11-01
|
| Saila: | Haematologica |
| Sarrera elektronikoa: | https://haematologica.org/article/view/7198 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|